---
figid: PMC6514318__jkns-2019-0033f1
figtitle: Molecular genetic pathways in long-term epilepsy-associated tumors (LEATs)
  and pediatric type diffuse low-grade glioma (DLGG)
organisms:
- NA
pmcid: PMC6514318
filename: jkns-2019-0033f1.jpg
figlink: /pmc/articles/PMC6514318/figure/f1-jkns-2019-0033/
number: F1
caption: Molecular genetic pathways in long-term epilepsy-associated tumors (LEATs)
  and pediatric type diffuse low-grade glioma (DLGG). Two major signaling pathways,
  the RAS-RAF-MAPK (green) and PI3K-AKT-mTOR (blue) play major role in LEATs. Upstream
  in receptor signaling, FGFR1 mutations have been described in dysembryoplastic neuroepithelial
  tumors. Activation of RAS-RAF-MAPK pathway by BRAF V600E mutation is frequently
  detected in gangliogliomas. BRAF and MEK1/2 are pharmacological targets for therapy
  (pink). MAPK activation is regulated by substrates of the PI3K–AKT–mTOR signaling
  cascade (red links). c-MYB/MYBL1 (purple) is altered in angiocentric gliomas. Genetic
  alterations described in LEATs are designated by a lightning bolt. Reprint from
  Blümcke et al. [] with permission from Springer Nature.
papertitle: Clinical Pearls and Advances in Molecular Researches of Epilepsy-Associated
  Tumors.
reftext: Ji Hoon Phi, et al. J Korean Neurosurg Soc. 2019 May;62(3):313-320.
year: '2019'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.8993343
figid_alias: PMC6514318__F1
figtype: Figure
organisms_ner:
- Homo sapiens
redirect_from: /figures/PMC6514318__F1
ndex: 236ff0bf-df14-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6514318__jkns-2019-0033f1.html
  '@type': Dataset
  description: Molecular genetic pathways in long-term epilepsy-associated tumors
    (LEATs) and pediatric type diffuse low-grade glioma (DLGG). Two major signaling
    pathways, the RAS-RAF-MAPK (green) and PI3K-AKT-mTOR (blue) play major role in
    LEATs. Upstream in receptor signaling, FGFR1 mutations have been described in
    dysembryoplastic neuroepithelial tumors. Activation of RAS-RAF-MAPK pathway by
    BRAF V600E mutation is frequently detected in gangliogliomas. BRAF and MEK1/2
    are pharmacological targets for therapy (pink). MAPK activation is regulated by
    substrates of the PI3K–AKT–mTOR signaling cascade (red links). c-MYB/MYBL1 (purple)
    is altered in angiocentric gliomas. Genetic alterations described in LEATs are
    designated by a lightning bolt. Reprint from Blümcke et al. [] with permission
    from Springer Nature.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - FGFR1
  - FGFR2
  - FGFR3
  - FGFR4
  - FGFRL1
  - IRS1
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - XYLT2
  - SOS1
  - SOS2
  - PTEN
  - PDK1
  - PDPK1
  - NF1
  - KRAS
  - HRAS
  - NRAS
  - BRAF
  - ZHX2
  - ARAF
  - RAF1
  - AKT1
  - AKT2
  - AKT3
  - MAPKAP1
  - MTOR
  - RICTOR
  - MLST8
  - DEPTOR
  - TSC2
  - MAP2K1
  - MAP2K2
  - TSC1
  - CCL26
  - EPHB2
  - MAPK1
  - MAPK3
  - RHEB
  - RHEBP1
  - SGK1
  - RPS6KA3
  - ELK1
  - KCNH4
  - KCNH8
  - MYB
  - MKNK2
  - MKNK1
  - MYC
  - PPP6R3
  - FKBP8
  - RPTOR
  - AKT1S1
  - SRF
  - ATG13
  - RB1CC1
  - ULK1
  - ATG101
  - CREB1
  - CREB3
  - CREB5
  - CREB3L1
  - CREB3L2
  - CREB3L3
  - CREB3L4
  - CREM
  - ATF1
  - ATF2
  - HIF1A
  - RPS6KB1
  - FOS
  - EIF4B
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - PGF
  - EIF4E
  - EIF4E2
  - EIF4E3
  - PLX4032
  - Selumetinib
  - AZD4266
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
